PIK3CB and cancer: Aberrant PI3K signaling in cancer can also occur via PTEN abnormalities including mutations, promotor hypermethylation or loss of heterozygosity; AKT isoform mutations or amplifications can occur as well (reviewed by Sadeghi and Gerber [55]).